Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carya illinoinensis pollen is a non-standardized allergenic extract from the pecan tree, developed and distributed by ALK-Abelló, Inc. under the brand name CENTER-AL. [1, 3] It is a biologic product formulated as a subcutaneous injection or suspension. The extract is used for allergen immunotherapy (also known as hyposensitization therapy) to treat allergic respiratory diseases like allergic rhinitis and asthma in individuals sensitized to pecan pollen. [6, 7] Treatment involves repeated subcutaneous administration to induce immunological tolerance to the pecan pollen allergens. [6] Additionally, the extract is utilized for diagnostic purposes through allergenic testing to identify pecan pollen allergies. [5] Due to the risk of severe systemic reactions, including anaphylaxis, it is intended for use by physicians experienced in administering such extracts and managing potential adverse events. [1, 7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carya illinoinensis pollen.